Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation Disorders | 5 | 2023 | 63 | 3.780 |
Why?
|
| Thrombelastography | 4 | 2023 | 47 | 2.700 |
Why?
|
| Plasma Exchange | 6 | 2021 | 29 | 2.390 |
Why?
|
| Blood Coagulation | 3 | 2023 | 91 | 1.620 |
Why?
|
| Anticoagulants | 8 | 2023 | 408 | 1.440 |
Why?
|
| Apolipoprotein A-I | 6 | 2014 | 71 | 1.380 |
Why?
|
| Thrombocytopenia | 4 | 2023 | 183 | 1.220 |
Why?
|
| Blood Platelets | 5 | 2022 | 149 | 1.210 |
Why?
|
| Erythrocyte Transfusion | 3 | 2022 | 60 | 1.160 |
Why?
|
| Blood Coagulation Tests | 4 | 2023 | 35 | 1.080 |
Why?
|
| Bone Marrow | 2 | 2019 | 435 | 1.070 |
Why?
|
| Atherosclerosis | 6 | 2010 | 244 | 1.020 |
Why?
|
| Peptides | 6 | 2010 | 639 | 1.020 |
Why?
|
| Heparin | 5 | 2023 | 175 | 0.950 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 96 | 0.900 |
Why?
|
| Anemia, Sickle Cell | 2 | 2022 | 131 | 0.890 |
Why?
|
| Organ Preservation | 1 | 2022 | 83 | 0.850 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 17 | 0.850 |
Why?
|
| Blood Transfusion | 2 | 2022 | 157 | 0.850 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2022 | 14 | 0.850 |
Why?
|
| Hemophilia A | 2 | 2022 | 8 | 0.830 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 141 | 0.790 |
Why?
|
| Thrombosis | 5 | 2023 | 296 | 0.770 |
Why?
|
| Lung Transplantation | 1 | 2022 | 175 | 0.760 |
Why?
|
| Blood Banks | 1 | 2019 | 7 | 0.710 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2019 | 14 | 0.710 |
Why?
|
| Bone Marrow Examination | 1 | 2019 | 48 | 0.710 |
Why?
|
| Bone Marrow Diseases | 1 | 2019 | 40 | 0.700 |
Why?
|
| Factor XI Deficiency | 1 | 2017 | 1 | 0.630 |
Why?
|
| Hemorrhage | 2 | 2023 | 268 | 0.610 |
Why?
|
| Oxygen | 1 | 2022 | 726 | 0.590 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2023 | 162 | 0.570 |
Why?
|
| Humans | 41 | 2023 | 86645 | 0.570 |
Why?
|
| Isoantibodies | 3 | 2022 | 114 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 1376 | 0.520 |
Why?
|
| Antibodies | 2 | 2022 | 350 | 0.520 |
Why?
|
| Receptors, LDL | 1 | 2014 | 53 | 0.490 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 222 | 0.490 |
Why?
|
| Drug Monitoring | 2 | 2017 | 118 | 0.480 |
Why?
|
| Factor Xa | 1 | 2013 | 4 | 0.480 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 325 | 0.480 |
Why?
|
| Pathology, Surgical | 1 | 2013 | 12 | 0.470 |
Why?
|
| Nanoparticles | 1 | 2014 | 157 | 0.440 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2022 | 12 | 0.430 |
Why?
|
| Platelet Aggregation | 2 | 2021 | 44 | 0.400 |
Why?
|
| Point-of-Care Testing | 3 | 2020 | 24 | 0.390 |
Why?
|
| Fibrinolysis | 2 | 2022 | 35 | 0.390 |
Why?
|
| International Normalized Ratio | 3 | 2020 | 38 | 0.390 |
Why?
|
| Extracorporeal Circulation | 2 | 2022 | 26 | 0.390 |
Why?
|
| Retrospective Studies | 6 | 2023 | 8491 | 0.390 |
Why?
|
| Referral and Consultation | 1 | 2013 | 328 | 0.380 |
Why?
|
| Hemolysis | 2 | 2022 | 61 | 0.380 |
Why?
|
| Molecular Mimicry | 3 | 2010 | 20 | 0.370 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 129 | 0.360 |
Why?
|
| Proline | 1 | 2009 | 57 | 0.340 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2019 | 20 | 0.340 |
Why?
|
| Hemoglobins | 3 | 2022 | 179 | 0.340 |
Why?
|
| Warfarin | 2 | 2019 | 103 | 0.330 |
Why?
|
| Acute-Phase Proteins | 1 | 2007 | 37 | 0.310 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 456 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 339 | 0.300 |
Why?
|
| Necrosis | 2 | 2019 | 204 | 0.290 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.250 |
Why?
|
| Erythrocytes | 2 | 2022 | 255 | 0.240 |
Why?
|
| Vaccines | 2 | 2022 | 80 | 0.240 |
Why?
|
| Fibrinolytic Agents | 2 | 2022 | 202 | 0.220 |
Why?
|
| von Willebrand Diseases | 1 | 2022 | 6 | 0.220 |
Why?
|
| Prothrombin Time | 2 | 2019 | 20 | 0.210 |
Why?
|
| Rivaroxaban | 1 | 2022 | 12 | 0.210 |
Why?
|
| Perfusion | 1 | 2022 | 203 | 0.210 |
Why?
|
| Dabigatran | 1 | 2022 | 24 | 0.210 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 243 | 0.210 |
Why?
|
| Formaldehyde | 1 | 2021 | 52 | 0.200 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 59 | 0.200 |
Why?
|
| Thrombin | 1 | 2021 | 61 | 0.200 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 2062 | 0.200 |
Why?
|
| Shear Strength | 1 | 2020 | 19 | 0.190 |
Why?
|
| Device Approval | 1 | 2020 | 13 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 28 | 0.190 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 72 | 0.190 |
Why?
|
| Fibrinogen | 1 | 2020 | 56 | 0.190 |
Why?
|
| Viscosity | 1 | 2020 | 46 | 0.190 |
Why?
|
| Elasticity | 1 | 2020 | 94 | 0.190 |
Why?
|
| Vibration | 1 | 2020 | 49 | 0.190 |
Why?
|
| Symptom Assessment | 1 | 2020 | 65 | 0.190 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2020 | 45 | 0.190 |
Why?
|
| Male | 9 | 2022 | 40967 | 0.190 |
Why?
|
| Reference Values | 1 | 2021 | 674 | 0.190 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 3030 | 0.180 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.180 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 314 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2020 | 98 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 127 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 196 | 0.180 |
Why?
|
| Lipoproteins, LDL | 2 | 2010 | 83 | 0.180 |
Why?
|
| Transfusion Medicine | 1 | 2019 | 3 | 0.180 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2019 | 12 | 0.180 |
Why?
|
| Vaccination | 1 | 2021 | 254 | 0.180 |
Why?
|
| CD47 Antigen | 1 | 2019 | 13 | 0.180 |
Why?
|
| HLA-A24 Antigen | 1 | 2019 | 20 | 0.180 |
Why?
|
| Anemia | 1 | 2020 | 128 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 170 | 0.180 |
Why?
|
| Thrombolytic Therapy | 1 | 2022 | 220 | 0.180 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2019 | 21 | 0.180 |
Why?
|
| Equipment Design | 1 | 2020 | 406 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 151 | 0.170 |
Why?
|
| ABO Blood-Group System | 1 | 2019 | 62 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 293 | 0.170 |
Why?
|
| Ultrasonography | 1 | 2021 | 695 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1991 | 0.170 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2018 | 8 | 0.170 |
Why?
|
| Platelet Factor 4 | 3 | 2022 | 11 | 0.160 |
Why?
|
| Myositis Ossificans | 1 | 2017 | 3 | 0.160 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 148 | 0.160 |
Why?
|
| Factor VIII | 1 | 2017 | 7 | 0.150 |
Why?
|
| Animals | 9 | 2023 | 26582 | 0.150 |
Why?
|
| Administration, Oral | 2 | 2022 | 684 | 0.150 |
Why?
|
| Mice | 5 | 2023 | 11352 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 763 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 930 | 0.140 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cesarean Section | 1 | 2017 | 137 | 0.140 |
Why?
|
| Lung | 1 | 2022 | 1170 | 0.140 |
Why?
|
| Female | 8 | 2020 | 44534 | 0.140 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 42 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2017 | 206 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 826 | 0.130 |
Why?
|
| Protein Structure, Secondary | 3 | 2010 | 330 | 0.120 |
Why?
|
| Laboratories, Hospital | 1 | 2013 | 7 | 0.120 |
Why?
|
| Adult | 5 | 2021 | 25648 | 0.120 |
Why?
|
| Biological Assay | 1 | 2013 | 78 | 0.120 |
Why?
|
| Factor Xa Inhibitors | 1 | 2013 | 22 | 0.120 |
Why?
|
| United States | 3 | 2020 | 6674 | 0.120 |
Why?
|
| Middle Aged | 6 | 2021 | 25028 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3092 | 0.110 |
Why?
|
| Aged | 4 | 2020 | 18415 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 429 | 0.110 |
Why?
|
| Drug Overdose | 1 | 2013 | 65 | 0.110 |
Why?
|
| Neoplasms | 2 | 2019 | 2898 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 878 | 0.110 |
Why?
|
| Platelet Count | 2 | 2021 | 92 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 731 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 1163 | 0.100 |
Why?
|
| Aryldialkylphosphatase | 1 | 2010 | 6 | 0.100 |
Why?
|
| Serum Amyloid A Protein | 1 | 2010 | 25 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2501 | 0.090 |
Why?
|
| Pregnancy | 1 | 2017 | 2894 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 154 | 0.090 |
Why?
|
| Protein Transport | 2 | 2010 | 411 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2010 | 38 | 0.090 |
Why?
|
| Epitopes | 1 | 2010 | 255 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 364 | 0.090 |
Why?
|
| Spleen | 1 | 2010 | 430 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 121 | 0.090 |
Why?
|
| Biotinylation | 1 | 2009 | 41 | 0.090 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 222 | 0.090 |
Why?
|
| Biomimetic Materials | 1 | 2009 | 22 | 0.090 |
Why?
|
| Body Weight | 1 | 2010 | 459 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7993 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2009 | 347 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 268 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2015 | 3613 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 503 | 0.080 |
Why?
|
| Kinetics | 1 | 2009 | 1513 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1924 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1851 | 0.070 |
Why?
|
| Disease Management | 2 | 2018 | 327 | 0.070 |
Why?
|
| Protein Binding | 1 | 2009 | 1456 | 0.070 |
Why?
|
| Inflammation | 1 | 2010 | 920 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2007 | 971 | 0.060 |
Why?
|
| Child | 1 | 2015 | 6928 | 0.060 |
Why?
|
| Ristocetin | 1 | 2022 | 1 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 5976 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 127 | 0.060 |
Why?
|
| von Willebrand Factor | 1 | 2022 | 37 | 0.060 |
Why?
|
| Pathologists | 1 | 2022 | 24 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2022 | 69 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2022 | 18 | 0.050 |
Why?
|
| Adolescent | 1 | 2015 | 8982 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 12 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 376 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 51 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 74 | 0.050 |
Why?
|
| Cytapheresis | 1 | 2021 | 1 | 0.050 |
Why?
|
| Filtration | 1 | 2021 | 25 | 0.050 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 27 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 153 | 0.050 |
Why?
|
| Cell Separation | 1 | 2021 | 196 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2022 | 989 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 112 | 0.050 |
Why?
|
| Plasma | 1 | 2019 | 50 | 0.050 |
Why?
|
| Vitamin K | 1 | 2019 | 25 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1014 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 589 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 6 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 19 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 172 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 73 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 119 | 0.040 |
Why?
|
| Ossification, Heterotopic | 1 | 2017 | 31 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 335 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 93 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 263 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 240 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 3968 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1036 | 0.020 |
Why?
|
| Clusterin | 1 | 2010 | 13 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2009 | 94 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 356 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1531 | 0.020 |
Why?
|